Latest Life Sciences News

Lendlease Group has reported a robust turnaround in its half-year results, posting an operating profit after tax of $122 million and advancing its strategic capital recycling initiatives. The company is on track to reduce gearing and enhance operational efficiency amid ongoing market challenges.

Lendlease Group has reported a statutory profit after tax of $48 million for the half year ended December 2024, reversing a prior loss and announcing a 6.0 cent interim distribution. The company is advancing key asset sales including Capella Capital and its US Military Housing business as part of its strategic transformation.

Charter Hall Social Infrastructure REIT delivered a solid 2025 half-year performance, maintaining distribution guidance while enhancing its portfolio through key acquisitions and divestments. The REIT’s outlook brightens with an increased full-year distribution forecast.

Vitrafy Life Sciences reports strong progress in cryopreservation technology development and US market expansion following a successful $35 million IPO. The company highlights improved biological sample preservation outcomes and strategic commercial milestones.

Vitrafy Life Sciences reported a dramatic increase in half-year losses to $25.7 million, yet successfully raised $35 million through an IPO to fuel its cryopreservation technology expansion.

AdAlta Limited has bolstered its leadership team and progressed its 'East to West' cellular therapy strategy alongside its lead drug candidate AD-214, despite a tightening cash position. The company’s recent non-binding term sheet and new clinical data signal promising momentum in its biotech pipeline.

Vitrafy Life Sciences reports strong Q2 FY2025 progress, marked by a successful $35 million IPO, promising validation results in animal and human health, and strategic expansion into North America.

Bluechiip Limited advances its strategic repositioning with a new licensing agreement valued up to USD 750,000 alongside ongoing efforts to lift its trading suspension and grow sales.

Microba Life Sciences reports a remarkable 102% revenue increase in Q2 FY25, driven by strong sales of its MetaXplore test in Australia and promising early traction in the UK. The company also advances its therapeutic pipeline with key clinical milestones.

Microba Life Sciences reported a robust Q2 FY25 with revenue more than doubling year-on-year, driven by strong sales of its MetaXplore microbiome test in Australia and promising early adoption in the UK.

AnteoTech has marked a pivotal quarter with its first commercial Ultranode™ order shipped to Mercedes-Benz and a $4.3 million capital raise to accelerate growth in clean energy and life sciences.

Bioxyne Limited has reported a remarkable 77% jump in revenue for Q2 FY2025, alongside positive operating cash flow, as it prepares to expand manufacturing capacity and enter new international markets.